Syndax Pharmaceuticals, Inc (Nasdaq: SNDX), a clinical stage biopharmaceutical company, announced on Wednesday that it has named Martin H Huber, MD as a new director.

Dr Huber has more than 20 years of academic, biotechnology, and pharmaceutical drug development experience. He is currently the President of R&D and Chief Medical Officer of Xilio Therapeutics, Inc. He has held the position of senior vice president, chief medical officer at TESARO, Inc, becoming senior vice president, Clinical following its acquisition by GlaxoSmithKline plc. He has also held the position of vice president, Oncology Clinical Research at Merck Research Laboratories.

Huber has an MD from Baylor College of Medicine.